DAB1-AS1: A Protein Implicated in Neurological Disorders and may be a Drug or Biomarker

Target Name: DAB1-AS1

NCBI ID: G101926890

DAB1-AS1

Other Name(s): DAB1-AS1 variant 1 | DAB1 antisense RNA 1

DAB1-AS1: A Protein Implicated in Neurological Disorders and may be a Drug or Biomarker

DAB1-AS1, also known as DAB1-AS1 variant 1, is a protein that is expressed in the brain and is involved in the regulation of cell survival and proliferation. The DAB1 gene is located on chromosome 12 and has been implicated in the development and progression of various neurological and psychiatric disorders.

The DAB1-AS1 protein is a member of the Asparagine/Aspartic Acid (ASP) domain family, which is known for its role in protein structure and function. The DAB1-AS1 protein has a unique structure that consists of a long N-terminus, a middle transmembrane region, and a C-terminus. The N-terminus of the protein contains a unique farnesylated cysteine residue, which is important for the protein's stability and localization in the brain.

The middle transmembrane region of the DAB1-AS1 protein is known for its role in the regulation of cell survival and proliferation. This region contains multiple conserved tyrosine residues, which are known to play important roles in the regulation of protein function. The C-terminus of the protein is involved in the protein's interaction with other proteins and is known for its role in the regulation of protein stability.

DAB1-AS1 has been implicated in the development and progression of various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and depression. Studies have shown that DAB1-AS1 is overexpressed in the brains of individuals with these disorders and that overexpression of the protein can lead to the misfolding and aggregation of beta-amyloid plaques, a hallmark of these disorders.

In addition to its role in the development and progression of these disorders, DAB1-AS1 is also a potential drug target. Studies have shown that DAB1-AS1 can be targeted by small molecules and that inhibition of the protein's activity can lead to the inhibition of the formation of beta-amyloid plaques. This suggests that DAB1-AS1 may be an effective target for the treatment of these disorders.

DAB1-AS1 is also a potential biomarker for the evaluation of these disorders. The protein is expressed in the brain and is involved in the regulation of cell survival and proliferation, which suggests that it may be an informative biomarker for the assessment of the severity and progression of these disorders.

In conclusion, DAB1-AS1 is a protein that is expressed in the brain and is involved in the regulation of cell survival and proliferation. The protein has a unique structure and is known for its role in the regulation of protein function. Its role in the development and progression of various neurological and psychiatric disorders makes it an attractive target for drug development and as a potential biomarker for the evaluation of these disorders. Further research is needed to fully understand the protein's role in the regulation of brain function and its potential as a drug and biomarker.

Protein Name: DAB1 Antisense RNA 1

The "DAB1-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DAB1-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets